Literature DB >> 7557847

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.

Y Shiratori1, S Shiina, M Imamura, N Kato, F Kanai, T Okudaira, T Teratani, G Tohgo, N Toda, M Ohashi.   

Abstract

Characteristics of 205 consecutive patients with hepatocellular carcinoma (HCC) admitted during 1990 to 1993 have been analyzed from the standpoint of hepatitis viral infection in Japan. Among 205 HCC patients, 71% of the patients showed positivity for hepatic C virus (HCV) antibody alone, 13% showed positivity both for HCV and HBV (HCV/HBV) antibody, 11% demonstrated HBsAg alone, and negativity of both HCV and HBV antibody in 4% only. Positivity to both HCV antibody and HBsAg was demonstrated in 1% only. Mean detection age of HCVAb-positive HCC as well as both HCV/HBV antibody-positive HCC was 62 +/- 7 years, in contrast to 52 +/- 13 years in HCC with HBsAg (P < .05). Male-to-female ratio among HCVAb-positive HCC was 3.3:1, in contrast to 5.5:1 among the HCV/HBVAb-positive HCC and 7:1 among HBsAg-positive HCC, but there was no significant difference in the gender distribution between these groups. More than 60% of HCVAb-positive HCC and HCV/HBVAb-positive HCC were classified into the stage of Child B and C, whereas 65% of HBsAg-positive HCC was at the stage of Child A. The severity of liver disease was confirmed by liver histology, indicating that more than 70% of the HCVAb-positive HCC and the HCV/HBVAb-positive HCC showed cirrhosis, in contrast to 50% among the HBsAg-positive HCC. Three-year survival rate of HCV Ab-positive HCC and HBV/HCVAb-positive HCC was 68% and 56%, respectively, in contrast to 47% in HBsAg-positive HCC.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7557847     DOI: 10.1016/0270-9139(95)90605-3

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  84 in total

1.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Male-specific W4P/R mutation in the pre-S1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients.

Authors:  Seoung-Ae Lee; Ki-Jeong Kim; Dong-Won Kim; Bum-Joon Kim
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

3.  Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.

Authors:  R Tateishi; H Yoshida; S Shiina; H Imamura; K Hasegawa; T Teratani; S Obi; S Sato; Y Koike; T Fujishima; M Makuuchi; M Omata
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Baseline characterization of patients aged 70 years and above with hepatocellular carcinoma.

Authors:  Makoto Nakamuta; Shusuke Morizono; Motoyuki Kohjima; Kazuhiro Kotoh; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

5.  Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Mayumi Funagayama; Masahiro Kai; Kazuhiro Otani; Jiro Ohuchida
Journal:  J Gastrointest Surg       Date:  2007-11-13       Impact factor: 3.452

6.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Soo Cheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

8.  Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takamasa Ohki; Takahisa Sato; Ryota Masuzaki; Jun Imamura; Eriko Goto; Tadashi Goto; Hideo Yoshida; Shuntaro Obi; Shinpei Sato; Fumihiko Kanai; Haruhiko Yoshida; Masao Omata
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

Review 9.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

10.  The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.